Previous Section
Review Articles
31. Immunotherapy in chronic myelogenous leukemia.
- Author
- Guilhot F; Roy L; Martineua G; Guilhot J; Millot F;
- Institution
- Department of Oncology-Hematology and Cell Therapy, Clinical Research Centre, Centre Hospitalier Universitaire de Poitiers, France. e-mail: f.guilhot@chu-poitiers.fr
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S64-70.
- Abstract URL
- Click here to view abstract
32. Monitoring patients with chronic myeloid leukemia receiving Abl tyrosine kinase inhibitor therapy.
- Author
- Oehler V; Radich JP;
- Institution
- Clinical Research Division, Program in Genetics and Genomics, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S58-63.
- Abstract URL
- Click here to view abstract
33. Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
- Author
- Jabbour E; Cortes J; O'Brien S; Rios MB; Giles F; Kantarjian H;
- Institution
- Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.
- Journal
- Clin Lymphoma Myeloma. 2007 Mar;7 Suppl 2:S51-7.
- Abstract URL
- Click here to view abstract
34. Imatinib mesylate for the treatment of chronic myeloid leukemia.
- Author
- Soverini S; Martinelli G; Iacobucci I; Baccarani M;
- Institution
- Department of Hematology & Oncological Sciences "Lorenzo e Ariosto Seragnoli" University of Bologna, Via Massarenti 9, 40138 Bologna, Italy. simona.soverini@tin.it
- Journal
- Expert Rev Anticancer Ther. 2008 Jun;8(6):853-64.
- Abstract URL
- Click here to view abstract
35. Molecular diagnosis and monitoring in the clinical management of patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors.
- Author
- Ou J; Vergilio JA; Bagg A;
- Institution
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104-4283, USA.
- Journal
- Am J Hematol. 2008 Apr;83(4):296-302.
- Abstract URL
- Click here to view abstract
36. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors?
- Author
- Maziarz RT;
- Institution
- Bone Marrow Transplantation Program, Oregon Health and Science University, Portland, Oregon 97201, USA. maziarzr@ohsu.edu
- Journal
- Curr Opin Hematol. 2008 Mar;15(2):127-33.
- Abstract URL
- Click here to view abstract
37. Homoharringtonine for the treatment of chronic myelogenous leukemia.
- Author
- Quintas-Cardama A; Cortes J;
- Institution
- Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1515 Holcombe Blvd., Houston, TX 77030, USA. aquintas@mdanderson.org
- Journal
- Expert Opin Pharmacother. 2008 Apr;9(6):1029-37.
- Abstract URL
- Click here to view abstract
38. Getting to the stem of chronic myeloid leukaemia.
- Author
- Savona M; Talpaz M;
- Institution
- University of Michigan, Internal Medicine-Hematology Oncology, 1500 East Medical Center Drive, Ann Arbor, Michigan 48109-45936, USA. msavona@med.umich.edu
- Journal
- Nat Rev Cancer. 2008 May;8(5):341-50.
- Abstract URL
- Click here to view abstract
39. Emerging drugs in chronic myelogenous leukaemia.
- Author
- Bocchia M; Forconi F; Lauria F;
- Institution
- Universita di Siena, Sezione di Ematologia e Trapianti, Dipartimento di Medicina Clinica e Scienze Immunologiche, AOUS, Viale Bracci--53100 Siena, Italy. bocchia@unisi.it
- Journal
- Expert Opin Emerg Drugs. 2006 Nov;11(4):651-64.
- Abstract URL
- Click here to view abstract
40. Management of patients with resistant or refractory chronic myelogenous leukemia.
- Author
- Quintas-Cardama A; Cortes J;
- Institution
- Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
- Journal
- Oncology (Williston Park). 2008 Apr 15;22(4):430-7; discussion 437, 442, 446 passim.
- Abstract URL
- Click here to view abstract
